Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Muzi

Showing results (31-40 of 89) with videos related to

Pageof 9
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 23, 2011
Multiagent PET for risk characterization in sarcomaJanet F Eary, Jeanne M Link, Mark Muzi, et al.
Nuclear Medicine and Biology|November 26, 2008
Rapid solid-phase extraction method to quantify [(11)C]-verapamil, and its [(11)C]-metabolites, in human and macaque plasmaJashvant D Unadkat, Francisco Chung, Lucy Sasongko, et al.
Clinical Pharmacology and Therapeutics|June 18, 2005
Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomographyLucy Sasongko, Jeanne M Link, Mark Muzi, et al.
Journal of Medical Imaging (Bellingham, Wash.)|December 5, 2017
Assessment of a statistical AIF extraction method for dynamic PET studies with <sup>15</sup>O water and <sup>18</sup>F fluorodeoxyglucose in locally advanced breast cancer patientsFinbarr O'Sullivan, Janet N O'Sullivan, Jian Huang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 8, 2005
Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancerMark Muzi, Hubert Vesselle, John R Grierson, et al.
Journal of the American Statistical Association|October 16, 2009
Nonparametric Residue Analysis of Dynamic PET Data With Application to Cerebral FDG Studies in NormalsFinbarr O'Sullivan, Mark Muzi, Alexander M Spence, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumorsHubert Vesselle, John Grierson, Mark Muzi, et al.
Magnetic Resonance Imaging|July 24, 2012
Quantitative assessment of dynamic PET imaging data in cancer imagingMark Muzi, Finbarr O'Sullivan, David A Mankoff, et al.
Molecular Imaging and Biology|March 28, 2009
NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studiesAlexander M Spence, Mark Muzi, Jeanne M Link, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2006
Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomasMark Muzi, Alexander M Spence, Finbarr O'Sullivan, et al.
Pageof 9

Showing results (31-40 of 89) with videos related to

Sort By:
Pageof 9
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 23, 2011
Multiagent PET for risk characterization in sarcomaJanet F Eary, Jeanne M Link, Mark Muzi, et al.
Nuclear Medicine and Biology|November 26, 2008
Rapid solid-phase extraction method to quantify [(11)C]-verapamil, and its [(11)C]-metabolites, in human and macaque plasmaJashvant D Unadkat, Francisco Chung, Lucy Sasongko, et al.
Clinical Pharmacology and Therapeutics|June 18, 2005
Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomographyLucy Sasongko, Jeanne M Link, Mark Muzi, et al.
Journal of Medical Imaging (Bellingham, Wash.)|December 5, 2017
Assessment of a statistical AIF extraction method for dynamic PET studies with <sup>15</sup>O water and <sup>18</sup>F fluorodeoxyglucose in locally advanced breast cancer patientsFinbarr O'Sullivan, Janet N O'Sullivan, Jian Huang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 8, 2005
Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancerMark Muzi, Hubert Vesselle, John R Grierson, et al.
Journal of the American Statistical Association|October 16, 2009
Nonparametric Residue Analysis of Dynamic PET Data With Application to Cerebral FDG Studies in NormalsFinbarr O'Sullivan, Mark Muzi, Alexander M Spence, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumorsHubert Vesselle, John Grierson, Mark Muzi, et al.
Magnetic Resonance Imaging|July 24, 2012
Quantitative assessment of dynamic PET imaging data in cancer imagingMark Muzi, Finbarr O'Sullivan, David A Mankoff, et al.
Molecular Imaging and Biology|March 28, 2009
NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studiesAlexander M Spence, Mark Muzi, Jeanne M Link, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2006
Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomasMark Muzi, Alexander M Spence, Finbarr O'Sullivan, et al.
Pageof 9